Tags & Categorías

Sandoz will appeal District Court of New Jersey ruling in biosimilar Erelzi® (etanercept-szzs) US pa...

Sandoz, a Novartis division and a global leader in biosimilars, today announced that the United States District Court of New Jersey ruled against Sand...

Ahead of Biosimilar Competition, Ranibizumab Gets a Positive CHMP Opinion for New Indication

Novartis, developer of the brand-name Lucentis, announced on Friday that the European Medicines Agency’s Committee for Medicinal Products for Human ...

Sandoz Enrolls First Patient in Study of Proposed Denosumab Biosimilar, GP2411

Sandoz announced today that it has enrolled its first patient in a combined phase 1 and phase 3 study of its proposed denosumab biosimilar versus EU-a...

EMA to Review Samsung Bioepis' Bevacizumab Biosimilar, SB8

Samsung Bioepis has announced that the European Medicines Agency (EMA) has accepted for review its market authorization application for SB8, a propose...

¿Qué barreras impiden la llegada de una oleada de biosimilares al mercado?

Los productores de biosimilares consideran que hay demasiados obstáculos hasta que logran comercializarlos

Biosimilares: la evolución del mercado será "más compleja" que en genéricos

El presidente de BioSim señala que médicos, farmacéuticos, administraciones y pacientes serán clave en su desarrollo.

Andalucía: los profesionales reclaman directrices para los biosimilares

Que existe un posicionamiento favorable de los profesionales sanitarios, sociedades científicas, pacientes y administraciones públicas hacia el uso ...

Switching to Biosimilar Rituximab, Truxima, Is Effective and Well Tolerated in Patients With RA

Recently, researchers reported 72-week results from a phase 3 trial of biosimilar rituximab, CT-P10 (Truxima), in patients with rheumatoid arthritis (...

European Medicines Agency accepted first “China-Developed” biosimilar – Henlius HLX02 MAA for review

Henlius, a biotech company in China developing both biosimilar and innovative biologics, announced that the European Medicines Agency (EMA) has offici...

Biogen presenta datos de práctica clínica con sus biosimilares de etanercept, infliximab y adalimuma...

Biogen ha anunciado la presentación de nuevos datos de práctica clínica de sus biosimilares de etanercept, infliximab y adalimumab en el Congreso E...